Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Introduction: Intravenous (IV) administration of isatuximab (Isa) in combination with pomalidomide and dexamethasone (Pd) is approved for patients (pts) with re